In recent years, studies have shown that besides type II diabetes, metformin also increases the radiosensitivity of various cancers [26,27] and improves the effect of radiotherapy through the NF-κB pathway [28,29,30]. Here, NFKB1 is linked to type 2 diabetes mellitus.